Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.

Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

Carisma Therapeutics Inc

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a poster session at the Society for Immunotherapy of Cancer ("SITC") Annual Meeting in Houston, Texas, on November 8, 2024.

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Get a deeper insight into the potential performance of Moderna (MRNA) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for

Align Technology

A. O. Smith

Centene

Elevance Health Inc

Enphase Energy

Erie Indemnity

First Solar

Genuine Parts

Humana

Mohawk Industries

Qorvo

Super Micro Computer

Teradyne

Super Micro joined the list after a 33% drop on Wednesday.

These are the S&P 500's biggest laggards for October, down by as much as 29%

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ET UBS Global Healthcare Conference, on Wednesday, November 13th at 3:30pm PT Jefferies London Healthcare Conference, on Thursday, November 21st at 2:00pm GT A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

Moderna to Present at Upcoming Conferences in November 2024

In the most recent trading session, Moderna (MRNA) closed at $55.22, indicating a +0.77% shift from the previous trading day.

Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider

Delray Beach, FL, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The global mRNA synthesis and manufacturing market is projected to grow from USD 2,231.4 million in 2024 to USD 2,958.3 million by 2029, at a CAGR of 5.8%. Key drivers include the growing focus on mRNA-based vaccines, expanding therapeutic applications, advancements in synthesis technology, and industry collaborations. Challenges such as high production costs, stability, and scalability remain hurdles. The rising demand for personalized medicine, particularly in cancer and rare genetic disorder therapies, is accelerating market growth, with major players like BioNTech and Moderna leading innovations. Artificial intelligence is also transforming the sector, optimizing drug development and manufacturing processes. Key opportunities lie in advancements in drug delivery technologies, while North America remains the largest regional market due to significant investments and mRNA's proven efficacy in COVID-19 vaccines.

mRNA Synthesis & Manufacturing Market to Hit USD 2958.3 million by 2029 with 5.8% CAGR | MarketsandMarkets™

The drug maker's shares have dropped 46% so far this year and 56% in the past three months.

Moderna Stock Price Target Slashed. It's About Vaccines.

Merck

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB (N2) non-sma.

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.

Moderna Named a Top Employer by Science for Tenth Consecutive Year

Moderna, Inc.'s share price has weakened due to declining COVID-19 vaccine demand, but its diverse asset portfolio supports future growth and returns. The company is focusing on respiratory vaccines, including RSV, Flu, and COVID-19 variants, to sustain and grow its revenue streams. Despite massive R&D expenditures and significant losses, Moderna's development portfolio, including oncology and other vaccines, holds substantial long-term potential.

We Think Moderna Still Has A Future

Moderna (MRNA) reachead $53.80 at the closing of the latest trading day, reflecting a -0.55% change compared to its last close.

Why Moderna (MRNA) Dipped More Than Broader Market Today

Albemarle

Deere & Company

Fidelity National Information

General Electric

Microchip Technology

Earnings season for most S&P 500 companies is a time to post impressive growth. But a cohort of companies is about to shrink.

Don't Get Caught Holding 7 Stocks About To Shrink 30% Or More

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

GlaxoSmithKline

Novavax

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring.

3 Vaccine Stocks to Watch as Flu Season Approaches

Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell?

Is Moderna Stock A Sell After The Company Slashed Its R&D Budget?

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

Moderna Stock Falls 20% in a Month: Time to Sell or Hold?

GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.

GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%.

mRNA Therapeutics Industry Research 2024-2028 & Long-term Forecast to 2033: Emerging Self-Amplifying mRNA Platforms, Scalability and Flexibility Expected to Revolutionize Vaccine Development

The latest trading day saw Moderna (MRNA) settling at $57.73, representing a -0.96% change from its previous close.

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "mRNA Cancer Vaccines and Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA cancer vaccines and therapeutics market size has grown rapidly in recent years. It will grow from $52.85 billion in 2023 to $61.52 billion in 2024 at a compound annual growth rate (CAGR) of 16.4%. The mRNA cancer vaccines and therapeutics market size is expected to see rapid growth in the next few years. It will grow to $113.41 billion in 2028 at a compound annual growth rate (CAGR) of 16.5%.

mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way

CRISPR Therapeutics

2 Biotech Stocks That Are Screaming Buys This Month

iShares China Large-Cap ETF

GraniteShares 2x Long NVDA Daily ETF

T-Rex 2X Long NVIDIA Daily Target ETF

VanEck Vectors Semiconductor ETF

SPDR S&P 500 ETF Trust

U.S. Bancorp

Direxion Daily FTSE China Bull 3X Shares

Most investors who own ETFs prudently hold S&P 500 index funds. But thrill-seekers looking for bigger returns can find them with ETFs.

Who Says ETFs Are 'Boring?' These 10 Are Up 100% Or More This Year

Moderna (MRNA) concluded the recent trading session at $58.39, signifying a -0.56% move from its prior day's close.

News for Moderna Stock (MRNA)